Guerbet

Guerbet is a specialized contrast media pharmaceutical company headquartered in Villepinte, north-east of Paris. The company employs more than 1,200 employees, of whom about 160 are engaged in research and development. The company is listed in the CAC Small.

Company History

1901 synthesized the chemist Marcel Guerbet the iodine-containing compound Lipiodol. The potential suitability as X-ray contrast agent was recognized until 1918. 1926 it was then by André Guerbet, the son of Marcel Guerbet, brought the first iodinated X-ray contrast agent on the market. The diagnostic is still on the market. In 1927, the headquarters of the company was transferred to Saint- Ouen. Michel Guerbet, son of André Guerbet took over the company in 1964 from his father. In the same year the iodine diagnostic Telebrix ( Natriumioxitalamat ) was approved. 1968, the company headquarters was then moved to Aulnay -sous -Bois (northeast of Paris). 1979 was brought to the market with Hexabrix another iodinated X-ray contrast agent.

With the advent of MRI, the company developed a contrast agent for this imaging method. 1989 were taken as contrast agents for magnetic resonance imaging on the market Dotarem, 1993 Lumirem, 1995 and 2003 Endorem Artirem.

1992, a branch was established in Germany. The Guerbet GmbH is headquartered in Sulzbach (Taunus ).

In addition, the company has other offices, including Austria, Switzerland, Belgium, USA, China and Japan.